9vHPV Vaccine + mRNA-1273 Vaccine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Trial Timeline
Mar 28, 2022 → Dec 12, 2023
NCT ID
NCT05119855About 9vHPV Vaccine + mRNA-1273 Vaccine
9vHPV Vaccine + mRNA-1273 Vaccine is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT05119855. Target conditions include Papillomavirus Infections, Coronavirus Disease (COVID-19).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05119855 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections